For research use only. Not for therapeutic Use.
Pyrrophenone is a potent and specific cytosolic phospholipase A2α (cPLA2α) inhibitor with an IC50 value of 4.2 nM[1].
Pyrrophenone shows potent inhibition of arachidonic acid release, prostaglandin E2, thromboxane B2, and leukotriene B4 formation in human whole blood[1].
Pyrrophenone inhibits the production of arachidonic acid (AA) (IC50=24±1.7 nM), PGE2 (IC50=25±19 nM),, and LTC4 (IC50=14±6.7 nM),from THP-1 cells stimulated with A23187[1].
Pyrrophenone inhibits the production of AA (IC50=0.19±0.068 μM), PGE2 (IC50=0.20±0.047 μM), TXB2 (IC50=0.16±0.093 μM),and LTB4 (IC50=0.32±0.24 μM) from human whole blood stimulated with A23187[1].
Pyrrophenone (0.1-0.5 μM, 48 h) inhibits the growth of PC-PTC3 and PCCl3 cells[2].
Pyrrophenone (administered i.p. at 20 mg/kg 30 min before LPS injection.) suppresses bronchoalveolar lavage (BAL) levels of leukotriene B4 (LTB4) and platelet activating factor (PAF)[3].
| Catalog Number | R064407 |
| CAS Number | 341973-06-6 |
| Synonyms | N-[[(2S,4R)-1-[2-(2,4-difluorobenzoyl)benzoyl]-4-tritylsulfanylpyrrolidin-2-yl]methyl]-4-[(Z)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]benzamide |
| Molecular Formula | C49H37F2N3O5S2 |
| Purity | ≥95% |
| InChI | InChI=1S/C49H37F2N3O5S2/c50-36-24-25-41(42(51)27-36)44(55)39-18-10-11-19-40(39)47(58)54-30-38(28-37(54)29-52-45(56)32-22-20-31(21-23-32)26-43-46(57)53-48(59)60-43)61-49(33-12-4-1-5-13-33,34-14-6-2-7-15-34)35-16-8-3-9-17-35/h1-27,37-38H,28-30H2,(H,52,56)(H,53,57,59)/b43-26-/t37-,38+/m0/s1 |
| InChIKey | XSCZRVUQXBBTRO-GYCZXHFISA-N |
| SMILES | C1C(CN(C1CNC(=O)C2=CC=C(C=C2)C=C3C(=O)NC(=O)S3)C(=O)C4=CC=CC=C4C(=O)C5=C(C=C(C=C5)F)F)SC(C6=CC=CC=C6)(C7=CC=CC=C7)C8=CC=CC=C8 |
| Reference | [1]. K Seno, et al. Pyrrolidine inhibitors of human cytosolic phospholipase A2. Part 2: synthesis of potent and crystallized 4-triphenylmethylthio derivative ‘pyrrophenone’. Bioorg Med Chem Lett. 2001 Feb 26;11(4):587-90. [2]. Stefania Mariggiò, et al. Cytosolic phospholipase A2 alpha regulates cell growth in RET/PTC-transformed thyroid cells. Cancer Res. 2007 Dec 15;67(24):11769-78. [3]. C-H Lee, et al. Mechanism of glutamine inhibition of cytosolic phospholipase a2 (cPLA2 ): Evidence of physical interaction between glutamine-Induced mitogen-activated protein kinase phosphatase-1 and cPLA2. Clin Exp Immunol. 2015 Jun;180(3):571-80. |
